Pharmacokinetics of fexofenadine following LPS administration to rats

Xenobiotica

Volumn 40, Issue 11, 2010, Pages 743-750

  Jaisue, S ^a   Gerber, J P ^b   Davey, A K ^b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Bioavailability; Clearance; Sepsis; Transport proteins

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; FEXOFENADINE; GLYCOPROTEIN P; ORGANIC ANION TRANSPORTER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TRANSPORT; DRUG URINE LEVEL; ESCHERICHIA COLI; IN VIVO STUDY; KIDNEY CLEARANCE; LIVER CLEARANCE; MALE; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ALLERGIC AGENTS; BIOLOGICAL AVAILABILITY; INFLAMMATION; INJECTIONS, INTRAVENOUS; LIPOPOLYSACCHARIDES; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, SPRAGUE-DAWLEY; TERFENADINE;

ANIMALIA; RATTUS;

EID: 77957941805     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.506929     Document Type: Article

References (31)

1. Ando H, Nishio Y, Ito K, Nakao A, Wang L, Zhao YL, Kitaichi K, Takagi K, Hasegawa T. (2001). Efect of endotoxin on P-glycoprotein-mediated biliary and renal excretion of rhodamine-123 in rats. Antimicrob Agents Chemother 45:3462-3467.
2. Bertini R, Bianchi M, Erroi A, Villa P, Ghezzi P. (1989). Dexamethasone modulation of in vivo efects of endotoxin, tumor necrosis factor, and interleukin-1 on liver cytochrome P-450, plasma fbrinogen, and serum iron. J Leukoc Biol 46:254-262.
3. Davey AK, Sim V, Tang EYF, Ma Z, Jaisue S, Wang J, Hiscock J. (2008). Infammation inducted alterations in kidney structure and function. Drug Metab Rev 40:211-212.
4. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
5. De Paepe P, Belpaire FM, Buylaert WA. (2002). Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 41:1135-1151.
6. Esplugues JV, Whittle BJ. (1989). Mechanisms contributing to gastric motility changes induced by PAF-acether and endotoxin in rats. Am J Physiol 256:G275-G282.
7. Frost F, Roach MJ, Kushner I, Schreiber P. (2005). Infammatory C-reactive protein and cytokine levels in asymptomatic people with chronic spinal cord injury. Arch Phys Med Rehabil 86:312-317.
8. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. (1999). Te role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153.
9. Hagenbuch B, Gui C. (2008). Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38:778-801.
10. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. (2001). Te efect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ter 69:114-121.
11. Hartmann G, Vassileva V, Piquette-Miller M. (2005). Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug Metab Dispos 33:820-828.
12. Irving K. (1982). Te phenomenon of the acute phase response. Ann NY Acad Sci 389:39-48.
13. Jepson MM, Cox M, Bates PC, Rothwell NJ, Stock MJ, Cady EB, Millward DJ. (1987). Regional blood fow and skeletal muscle energy status in endotoxemic rats. Am J Physiol 252:E581-E587.
14. Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, Piquette-Miller M. (2004). Suppression of drug-metabolizing enzymes and efux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos 32:20-27.
15. Kamath AV, Yao M, Zhang Y, Chong S. (2005). Efect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci 94:233-239.
16. Kikeri D, Pennell JP, Hwang KH, Jacob AI, Richman AV, Bourgoignie JJ. (1986). Endotoxemic acute renal failure in awake rats. Am J Physiol 250:F1098-F1106.
17. Kozak W, Poli V, Soszynski D, Conn CA, Leon LR, Kluger MJ. (1997). Sickness behavior in mice defcient in interleukin-6 during turpentine abscess and infuenza pneumonitis. Am J Physiol Regul Integr Comp Physiol, 272. R62130.
18. Leon LR, Conn CA, Glaccum M, Kluger MJ. (1996). IL-1 type I receptor mediates acute phase response to turpentine, but not lipopolysaccharide, in mice. Am J Physiol 271:R1668-R1675.
19. Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, Sugiyama Y. (2008). Involvement of multiple efux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 73:1474-1483.
20. McEvoy GK (Ed.) (2004). AHFS drug information, Bethesda, MD.
21. Milne RW, Larsen LA, Jørgensen KL, Bastlund J, Stretch GR, Evans AM. (2000). Hepatic disposition of fexofenadine: infuence of the transport inhibitors erythromycin and dibromosulphothalein. Pharm Res 17:1511-1515.
22. Mishra J, Zhang Q, Rosson JL, Moran J, Dopp JM, Neudeck BL. (2008). Lipopolysaccharide increases cell surface P-glycoprotein that exhibits diminished activity in intestinal epithelial cells. Drug Metab Dispos 36:2145-2149.
23. Miura M, Uno T, Tateishi T, Suzuki T. (2007). Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality 19:223-227.
24. Nadai M, Matsuda I, Wang L, Itoh A, Naruhashi K, Nabeshima T, Asai M, Hasegawa T. (1998). Granulocyte colony-stimulating factor enhances endotoxin-induced decrease in biliary excretion of the antibiotic cefoperazone in rats. Antimicrob Agents Chemother 42:2178-2183.
25. Parasrampuria R, Mehvar R. (2008). Hepatobiliary disposition of rhodamine 123 in isolated perfused rat livers. Xenobiotica 38:1263-1273.
26. Piquette-Miller M, Pak A, Kim H, Anari R, Shahzamani A. (1998). Decreased expression and activity of P-glycoprotein in rat liver during acute infammation. Pharm Res 15:706-711.
27. Strelevitz TJ, Foti RS, Fisher MB. (2006). In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to frst-pass and systemic clearance. J Pharm Sci 95:1334-1341.
28. Tahara H, Kusuhara H, Fuse E, Sugiyama Y. (2005). P-glycoprotein plays a major role in the efux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 33:963-968.
29. Tong Y, Zhang R, Ngo SN, Davey AK. (2006). Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. Clin Exp Pharmacol Physiol 33:685-689.
30. Wang P, Ba ZF, Chaudry IH. (1991). Increase in hepatic blood fow during early sepsis is due to increased portal blood fow. Am J Physiol 261:R1507-R1512.
31. Wallace JL, Steel G, Whittle BJ, Lagente V, Vargaftig B. (1987). Evidence for platelet-activating factor as a mediator of endo-toxin-induced gastrointestinal damage in the rat. Efects of three platelet-activating factor antagonists. Gastroenterology 93:765-773.